Brief: Scisparc Takes Major Step Forward With Ind Application Submitted To The FDA For Phase Iib Clinical Trial For Tourette Syndrome Treatment
18/09/2024 21:52
Scisparc Ltd SPRC.O :
* SCISPARC TAKES MAJOR STEP FORWARD WITH IND APPLICATION
SUBMITTED
TO THE FDA FOR PHASE IIB CLINICAL TRIAL FOR TOURETTE SYNDROME
TREATMENT
Source text for Eikon: ID:nGNX8ZTgXQ
Further company coverage: SPRC.O